SCP2 and early-onset autosomal dominant Alzheimer disease: The results showed that SCP2 significantly reversed the metabolic profile disorder in Alzheimer’s disease rats and played an important role in ameliorating Aβ25-35-induced cognitive dysfunction, attenuating oxidative damage, and reducing Aβ deposition in the hippocampus, which may provide new insight into the potential mechanisms of SCP2 treatment of AD (119).